Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.07 -0.92 (-1.08%)
Official Closing Price Updated: 7:00 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,586,791
Open 85.07
Bid (Size) 84.01 (1)
Ask (Size) 84.07 (1)
Prev. Close 84.99
Today's Range 83.88 - 85.48
52wk Range 73.31 - 120.30
Shares Outstanding 2,531,374,696
Dividend Yield 3.85%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger. 
Via Benzinga

Performance

YTD
-15.2%
-15.2%
1 Month
+0.0%
+0.0%
3 Month
+8.4%
+8.4%
6 Month
-8.0%
-8.0%
1 Year
-27.7%
-27.7%

More News

Read More
EU Rushes To Scrap Tariffs On US Goods To Unlock Lower American Auto Duties: These Exporters Stand To Gain Big
Via Benzinga
Topics World Trade
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
From Merck & Co., Inc.
Via Business Wire
Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside
Via Stocktwits
As the Market Rotates, This Healthcare ETF Is Leading the Way
Via MarketBeat
Topics ETFs
CSX, Intel, Palantir, Nvidia, Merck: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Via Stocktwits
Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts
Via MarketBeat
Topics ETFs Economy
HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform
Via Benzinga
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: S&P500 movers
Via Chartmill
Slocum Gordon Exits Stake in Kimberly-Clark Worth Nearly $3 Million
Via The Motley Fool
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
From Merck & Co., Inc.
Via Business Wire
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
2 Value Stocks on Our Watchlist and 1 Facing Challenges
Via StockStory
2 Top Dividend Stocks to Buy on the Dip
Via The Motley Fool
Topics Earnings Intellectual Property
MERCK & CO. INC. (NYSE:MRK) – A Strong Value Investment with Undervalued Potential
Via Chartmill
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life'
Via Benzinga
3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever
Via The Motley Fool
Topics Intellectual Property Stocks
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
Via The Motley Fool
Topics Retirement
MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period
Via StockStory
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Via Benzinga
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 84.07
When was Merck & Co last traded?
The last trade of Merck & Co was at 08/27/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 212.81B
How many shares of Merck & Co are outstanding?
Merck & Co has 213B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.